NASDAQ:REPL Replimune Group - REPL Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Replimune Group, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $18.80 -1.20 (-6.00%) (As of 03/22/2023 12:00 AM ET) Add Compare Share Share Today's Range$18.77▼$20.0650-Day Range$18.65▼$29.0952-Week Range$13.05▼$29.52Volume540,171 shsAverage Volume820,839 shsMarket Capitalization$1.07 billionP/E RatioN/ADividend YieldN/APrice Target$51.86 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability Replimune Group MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside175.8% Upside$51.86 Price TargetShort InterestBearish7.20% of Float Sold ShortDividend StrengthN/ASustainability-1.28Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.91) to ($2.83) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.11 out of 5 starsMedical Sector438th out of 986 stocksBiological Products, Except Diagnostic Industry78th out of 165 stocks 3.5 Analyst's Opinion Consensus RatingReplimune Group has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $51.86, Replimune Group has a forecasted upside of 175.8% from its current price of $18.80.Amount of Analyst CoverageReplimune Group has only been the subject of 2 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted7.20% of the float of Replimune Group has been sold short.Short Interest Ratio / Days to CoverReplimune Group has a short interest ratio ("days to cover") of 4.8.Change versus previous monthShort interest in Replimune Group has recently increased by 97.18%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldReplimune Group does not currently pay a dividend.Dividend GrowthReplimune Group does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreReplimune Group has received a 69.41% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for cancer" product. See details.Environmental SustainabilityThe Environmental Impact score for Replimune Group is -1.28. Previous Next 0.6 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for Replimune Group this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for REPL on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows2 people have added Replimune Group to their MarketBeat watchlist in the last 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Replimune Group insiders have not sold or bought any company stock.Percentage Held by Insiders23.80% of the stock of Replimune Group is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions87.83% of the stock of Replimune Group is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Replimune Group are expected to grow in the coming year, from ($2.91) to ($2.83) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Replimune Group is -6.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Replimune Group is -6.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioReplimune Group has a P/B Ratio of 2.16. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Replimune Group (NASDAQ:REPL) StockReplimune Group, Inc. is a clinical-stage biotechnology company, which engages in the development of oncolytic immunotherapy product candidates through immulytic platform. Its product candidates include RP1, RP2, and RP3. The firm's Oncolytic immunotherapy is a cancer treatment that exploits the ability of certain viruses to selectively replicate in and directly kill tumors, as well as induce a potent, patient-specific, anti-tumor immune response. The company was founded by Philip Astley-Sparke, Colin A. Love and Robert Coffin in March 2015 and is headquartered in Woburn, MA.Read More Receive REPL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Replimune Group and its competitors with MarketBeat's FREE daily newsletter. Email Address REPL Stock News HeadlinesMarch 17, 2023 | seekingalpha.comREPL Replimune Group, Inc.February 24, 2023 | finance.yahoo.comReplimune Group, Inc. (REPL) Loses -14.58% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerMarch 23, 2023 | Health Sector Insight (Ad)Penny Stock Shows Big PotentialThe $4.37 trillion wellness market and the little-known penny stock to get on radar now. February 9, 2023 | msn.comReplimune Group GAAP EPS of -$0.69 beats by $0.08February 9, 2023 | finance.yahoo.comReplimune Reports Fiscal Third Quarter Financial Results and Provides Corporate UpdateFebruary 7, 2023 | finance.yahoo.comReplimune to Present at the Virtual SVB Securities Global Biopharma ConferenceJanuary 6, 2023 | finance.yahoo.comRecent Price Trend in Replimune Group, Inc. (REPL) is Your Friend, Here's WhyJanuary 6, 2023 | finance.yahoo.comInstitutional investors may adopt severe steps after Replimune Group, Inc.'s (NASDAQ:REPL) latest 5.3% drop adds to a year lossesMarch 23, 2023 | Health Sector Insight (Ad)Penny Stock Shows Big PotentialThe $4.37 trillion wellness market and the little-known penny stock to get on radar now. January 6, 2023 | finance.yahoo.comWall Street Analysts Think Replimune Group, Inc. (REPL) Could Surge 87.88%: Read This Before Placing a BetJanuary 4, 2023 | it.tmcnet.comReplimune Appoints Former Sanofi U.S. Commercial Oncology Head, Chris Sarchi, as Chief Commercial Officer and Sushil Patel as Chief Strategy OfficerJanuary 3, 2023 | finance.yahoo.comReplimune to Present at the 41st Annual J.P. Morgan Healthcare ConferenceDecember 14, 2022 | finance.yahoo.comReplimune Breaks Out: Could Rise 30% From HereDecember 12, 2022 | finance.yahoo.comAnalyst Beefs Up Replimune Price Target As Recent Data Validates Treatment PlatformDecember 7, 2022 | marketwatch.comReplimune Shares Rally on Pipeline Advances >REPLDecember 7, 2022 | finance.yahoo.comReplimune Shares Surge After Early Data From Pretreated Melanoma PatientsDecember 7, 2022 | marketwatch.comReplimune, Roche to Develop RP3 in Colorectal Cancer, Hepatocellular Carcinoma >REPLDecember 7, 2022 | seekingalpha.comReplimune in pact with Roche to study cancer drug combosDecember 7, 2022 | finance.yahoo.comReplimune Enters into Clinical Collaboration Agreement with Roche for the Development of RP3 In Colorectal Cancer and Hepatocellular CarcinomaDecember 7, 2022 | finance.yahoo.comReplimune Announces Positive Initial Data from the Anti-PD1 Failed Melanoma Cohort of the IGNYTE Clinical Trial & an RP2/3 Program UpdateNovember 23, 2022 | finance.yahoo.comReplimune to Present at the Piper Sandler 34th Annual Healthcare ConferenceNovember 22, 2022 | finance.yahoo.comReplimune to Host Virtual Investor Event on December 7, 2022November 3, 2022 | finanznachrichten.deReplimune Group Inc: Replimune Reports Fiscal Second Quarter Financial Results and Provides Corporate UpdateOctober 15, 2022 | finance.yahoo.comReplimune Gets 33% Price Target Bump Ahead Of Upcoming Readouts. Analyst Lists The CatalystsOctober 14, 2022 | markets.businessinsider.comExpert Ratings for Replimune GroupAugust 24, 2022 | finance.yahoo.comBillionaires Are Scooping Up These 3 Beaten-Down Biotech StocksAugust 12, 2022 | seekingalpha.comReplimune: Recent Developments Strengthen Bull ThesisSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive REPL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Replimune Group and its competitors with MarketBeat's FREE daily newsletter. Email Address REPL Company Calendar Last Earnings11/04/2021Today3/23/2023Fiscal Year End3/31/2023Next Earnings (Estimated)5/18/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:REPL CUSIPN/A CIK1737953 Webwww.replimune.com Phone(781) 222-9600FaxN/AEmployees152Year Founded2015Price Target and Rating Average Stock Price Forecast$51.86 High Stock Price Forecast$70.00 Low Stock Price Forecast$34.00 Forecasted Upside/Downside+175.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($2.86) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-118,040,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-34.81% Return on Assets-30.81% Debt Debt-to-Equity Ratio0.09 Current Ratio23.58 Quick Ratio23.58 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$8.71 per share Price / Book2.16Miscellaneous Outstanding Shares56,650,000Free Float43,171,000Market Cap$1.07 billion OptionableNot Optionable Beta1.69 Key ExecutivesPhilip Astley-SparkeChief Executive Officer & DirectorRobert CoffinPresident & DirectorColin A. LoveChief Operating OfficerJean M. FranchiChief Financial Officer, Secretary & TreasurerPamela EspositoChief Business OfficerKey CompetitorsAdaptive BiotechnologiesNASDAQ:ADPTTwist BioscienceNASDAQ:TWSTInhibrxNASDAQ:INBXArcellxNASDAQ:ACLXREGENXBIONASDAQ:RGNXView All CompetitorsInsiders & InstitutionsVictory Capital Management Inc.Bought 576,487 shares on 3/10/2023Ownership: 1.018%Teachers Retirement System of The State of KentuckyBought 17,697 shares on 2/22/2023Ownership: 0.031%Alliancebernstein L.P.Bought 1,029 shares on 2/16/2023Ownership: 0.056%Alps Advisors Inc.Bought 6,763 shares on 2/15/2023Ownership: 0.068%Legal & General Group PlcBought 3,479 shares on 2/15/2023Ownership: 0.024%View All Insider TransactionsView All Institutional Transactions REPL Stock - Frequently Asked Questions Should I buy or sell Replimune Group stock right now? 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Replimune Group in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" REPL shares. View REPL analyst ratings or view top-rated stocks. What is Replimune Group's stock price forecast for 2023? 7 brokerages have issued 12 month price objectives for Replimune Group's stock. Their REPL share price forecasts range from $34.00 to $70.00. On average, they anticipate the company's share price to reach $51.86 in the next year. This suggests a possible upside of 175.8% from the stock's current price. View analysts price targets for REPL or view top-rated stocks among Wall Street analysts. How have REPL shares performed in 2023? Replimune Group's stock was trading at $27.20 at the beginning of the year. Since then, REPL shares have decreased by 30.9% and is now trading at $18.80. View the best growth stocks for 2023 here. Are investors shorting Replimune Group? Replimune Group saw a increase in short interest in the month of February. As of February 28th, there was short interest totaling 2,800,000 shares, an increase of 97.2% from the February 13th total of 1,420,000 shares. Based on an average daily trading volume, of 582,700 shares, the days-to-cover ratio is currently 4.8 days. Currently, 7.2% of the company's stock are sold short. View Replimune Group's Short Interest. When is Replimune Group's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 18th 2023. View our REPL earnings forecast. How were Replimune Group's earnings last quarter? Replimune Group, Inc. (NASDAQ:REPL) issued its quarterly earnings data on Thursday, November, 4th. The company reported ($0.56) earnings per share for the quarter, missing the consensus estimate of ($0.51) by $0.05. What ETFs hold Replimune Group's stock? ETFs with the largest weight of Replimune Group (NASDAQ:REPL) stock in their portfolio include Loncar Cancer Immunotherapy ETF (CNCR), ALPS Medical Breakthroughs ETF (SBIO), Virtus LifeSci Biotech Clinical Trials ETF (BBC), Invesco DWA Healthcare Momentum ETF (PTH), Harbor Disruptive Innovation ETF (INNO), Principal Healthcare Innovators ETF (BTEC), iShares Micro-Cap ETF (IWC) and SPDR S&P Biotech ETF (XBI). What other stocks do shareholders of Replimune Group own? Based on aggregate information from My MarketBeat watchlists, some companies that other Replimune Group investors own include Peabody Energy (BTU), Myovant Sciences (MYOV), Peabody Energy (BTUUQ), AVEO Pharmaceuticals (AVEO), Fate Therapeutics (FATE), Immunomedics (IMMU), Pfizer (PFE), SCYNEXIS (SCYX), Exelixis (EXEL) and Fulcrum Therapeutics (FULC). When did Replimune Group IPO? (REPL) raised $100 million in an initial public offering on Friday, July 20th 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Leerink Partners and BMO Capital Markets served as the underwriters for the IPO. What is Replimune Group's stock symbol? Replimune Group trades on the NASDAQ under the ticker symbol "REPL." Who are Replimune Group's major shareholders? Replimune Group's stock is owned by many different retail and institutional investors. Top institutional shareholders include Price T Rowe Associates Inc. MD (10.18%), Omega Fund Management LLC (6.76%), Atlas Venture Life Science Advisors LLC (4.22%), T. Rowe Price Investment Management Inc. (2.18%), Emerald Advisers LLC (2.38%) and Frazier Life Sciences Management L.P. (1.87%). Insiders that own company stock include Colin Love, Fund Iv LP Omega, Jason P Rhodes, Jean M Franchi, Pamela Esposito, Philip Astley-Sparke and Robert Coffin. View institutional ownership trends. How do I buy shares of Replimune Group? Shares of REPL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Replimune Group's stock price today? One share of REPL stock can currently be purchased for approximately $18.80. How much money does Replimune Group make? Replimune Group (NASDAQ:REPL) has a market capitalization of $1.07 billion. The company earns $-118,040,000.00 in net income (profit) each year or ($2.86) on an earnings per share basis. How many employees does Replimune Group have? The company employs 152 workers across the globe. How can I contact Replimune Group? Replimune Group's mailing address is 500 Unicorn Park, WOBURN MA, 01801. The official website for the company is www.replimune.com. The company can be reached via phone at (781) 222-9600 or via email at ir@replimune.com. This page (NASDAQ:REPL) was last updated on 3/23/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.